구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells) Second Affiliated Hospital of Guan…·FRα 1 trials |
|---|---|
Overview Program | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells |
Overview Company | Second Affiliated Hospital of Guangzhou Medical University |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Stage IV Ovarian Cancer; Testis Cancer, Refractory |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.. Glioblastoma is the most common cancer among primary brain tumors, however, its prognosis and treatment advances are very poor. Here, we investigated whether c-Met, FOLR1, and AXL proteins are promising targets for chimeric antigen receptor (CAR) T-cell therapy, for they are known to be over-expressed in a va… |
Clinical Safety signal | Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.. Glioblastoma is the most common cancer among primary brain tumors, however, its prognosis and treatment advances are very poor. Here, we investigated whether c-Met, FOLR1, and AXL proteins are promising targets for chimeric antigen receptor (CAR) T-cell therapy, for they are known to be over-expressed in a va… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells) Second Affiliated Hospital of Guan…·FRα 1 trials |
|---|---|
Overview Program | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells |
Overview Company | Second Affiliated Hospital of Guangzhou Medical University |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Stage IV Ovarian Cancer; Testis Cancer, Refractory |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.. Glioblastoma is the most common cancer among primary brain tumors, however, its prognosis and treatment advances are very poor. Here, we investigated whether c-Met, FOLR1, and AXL proteins are promising targets for chimeric antigen receptor (CAR) T-cell therapy, for they are known to be over-expressed in a va… |
Clinical Safety signal | Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.. Glioblastoma is the most common cancer among primary brain tumors, however, its prognosis and treatment advances are very poor. Here, we investigated whether c-Met, FOLR1, and AXL proteins are promising targets for chimeric antigen receptor (CAR) T-cell therapy, for they are known to be over-expressed in a va… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교